Territory Manager
SI-BONE
Territory Manager
SI-BONE
Minimally invasive sacroiliac joint implant provider
SI-BONE is a fast-growing, publicly traded medical device company that is an industry pioneer in minimally invasive sacropelvic solutions. Our mission is to help patients rise up and reach for the stars, and our vision is to work together as the global leader to make sacropelvic conditions universally recognized and effectively treated through innovation, evidence, education, and advocacy.
Territory Manager: North Carolina
Base salary $75,000
General Responsibilities:
Specific Responsibilities and Skills:
Expertise:
Knowledge, Education and Experience:
There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com/risks.
We are aware of active recruitment scams using the SI-BONE name, in which individuals pose as our recruiters and post fake remote job openings and make fake job offers on the Internet. Please note, we will never make an offer of employment without conducting multiple rounds of interviews face-to-face using secure video-conferencing technology. We will never ask candidates to cash checks or make a payment in order to be considered for a position. SI-BONE only uses company email addresses, which contain “@si-bone.com” to communicate with candidates.
If you believe you’ve been a victim of a phishing scam, please visit the Cybersecurity & Infrastructure Security Agency at https://www.cisa.gov/be-cyber-smart/report-incident learn how to report it.
SI-BONE focuses on treating sacroiliac joint dysfunction, a common source of lower back pain, by offering a minimally invasive implant system called iFuse. The iFuse Implant System is implanted surgically to stabilize the sacroiliac joint with a less invasive approach that aims for quicker recovery compared to traditional methods. The company gained FDA clearance for this implant, validating its use in patients. In 2018, SI-BONE went public on the NASDAQ, providing capital to expand research, development, and market presence. Its ongoing goal is to improve patient outcomes through education and continued development of sacroiliac joint treatments. Unlike broader orthopedic device makers, SI-BONE specializes in a targeted SI joint solution and builds its business around a single reusable implant technology and related surgical tools.
Explore more opportunities at SI-BONE